文献速递血液透析通路

初次动静脉内瘘成熟失败的血透患者二次血管通路的選擇

Choice of a second vascular access in hemodialysis patients whose initial arteriovenous fistula failed to mature.
PubMed 文献 · J Vasc Surg · 2018-06-21

该回顾性队列研究纳入92例初次动静脉内瘘(AVF)成熟失败后接受二次血管通路的患者(44例AVF,48例AVG),比较每年经皮或外科介入及导管相关菌血症(CRB)频率与费用。二次AVF组经皮介入次数少于AVG组(2.09 vs 2.61,P=0.004),CRB年费用更高($3405 vs $0,P=0.04),但总年费用无显著差异($19,477 vs $18,285,P=0.56)。

要点

  • 二次AVF组经皮介入次数少于二次AVG组(2.09 vs 2.61,P=0.004)。
  • 二次AVF组CRB年费用高于AVG组($3405 vs $0,P=0.04)。
  • 两组总年通路相关费用无显著差异($19,477 vs $18,285,P=0.56)。

核心结论

  • 二次AVF患者比二次AVG植入患者需要更多外科手术并发生更多菌血症并发症。
  • 接受二次AVF与AVG的血透患者通路总费用无显著差异。

研究设计与样本

  • 回顾性队列研究,纳入92例初次AVF成熟失败后接受二次血管通路的患者,其中44例AVF、48例AVG。
  • 通过计算机化血管通路数据库量化每年经皮或外科介入及CRB频率,费用依据门诊预期支付计划和诊断相关组费用表计算。

主要发现

  • 二次AVF组经皮介入次数少于AVG组(2.09 [95%CI 1.86-2.34] vs 2.61 [2.35-2.88];P=0.004)。
  • 二次AVF组外科介入次数有高于AVG组的趋势(1.21 [95%CI 1.04-1.40] vs 1.00 [0.84-1.17];P=0.08)。
  • 两组CRB住院年频率相似(0.40 [95%CI 0.31-0.52] vs 0.28 [0.20-0.38];P=0.07)。
  • 二次AVF组与AVG组经皮介入年费用中位数相似($3567 [IQR $1219-$4680] vs $4989 [$1570-$9752];P=0.14),外科介入年费用相似($6403 [$3494-$13,127] vs $4728 [$2563-$12,254];P=0.38)。
  • 二次AVF组CRB年费用高于AVG组($3405 [$0-$12,825] vs $0 [$0-$5477];P=0.04),总年通路相关费用无显著差异($19,477 [$9162-$36,916] vs $18,285 [$6850-$31,768];P=0.56)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We have previously shown that arteriovenous fistulas (AVFs) are more expensive to create and to maintain than arteriovenous grafts (AVGs) in patients undergoing their first access. Because those for whom this first access fails may be a more disadvantaged group, we hypothesized that the cost of a second access may be different from that in the primary access group. With this in mind, we compared access costs in patients receiving a secondary AVF or AVG after their initial AVF failed to mature. METHODS: This was a retrospective cohort study of 92 patients who received a second vascular access (44 AVFs and 48 AVGs) after their first AVF failed to mature. We quantified the yearly frequency of percutaneous or surgical access interventions and catheter-related bacteremias (CRBs) using a computerized vascular access database. The costs associated with access procedures were quantified using the outpatient prospective payment schedule, and those related to hospitalization for CRB were determined from the diagnosis-related groups fee schedule. RESULTS: Patients receiving an AVF had fewer percutaneous procedures than those receiving an AVG (2.09 [95% confidence interval, 1.86-2.34] vs 2.61 [2.35-2.88]; P = .004), tended to undergo surgical interventions more frequently (1.21 [1.04-1.40] vs 1.00 [0.84-1.17]; P = .08), and experienced a similar yearly frequency of CRB hospitalizations (0.40 [0.31-0.52 vs 0.28 [0.20-0.38]; P = .07). Patients with a secondary AVF vs an AVG had a similar median yearly cost of percutaneous access interventions ($3567 [interquartile range, $1219-$4680] vs $4989 [$1570-$9752]; P = .14) and surgical access procedures ($6403 [$3494-$13,127] vs $4728 [$2563-$12,254]; P = .38) but a higher annual cost for CRBs ($3405 [$0-$12,825] vs $0 [$0-$5477]; P = .04). The total yearly access-related cost was similar in both groups ($19,477 [$9162-$36,916] vs $18,285 [$6850-$31,768]; P = .56). CONCLUSIONS: Patients undergoing a secondary AVF required more surgical procedures and sustained more bacteremia complications than patients undergoing a secondary AVG implantation. There was no significant difference in the total cost of access care for hemodialysis patients receiving a secondary AVF vs AVG.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Al-Balas A, Lee T, Young CJ, et al. Choice of a second vascular access in hemodialysis patients whose initial arteriovenous fistula failed to mature. J Vasc Surg. 2018. PMID: 29937290. doi:10.1016/j.jvs.2018.03.419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。